Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Cancer Immunology, Immunotherapy

Volumn 67, Issue 5, 2018, Pages 825-834

  Kähler, Katharina C ^a   Eigentler, Thomas K ^b   Gesierich, Anja ^c   Heinzerling, Lucie ^d   Loquai, Carmen ^e   Meier, Friedegund ^f   Meiss, Frank ^g   Pföhler, Claudia ^h   Schlaak, Max ⁱ   Terheyden, Patrick ^j   Thoms, Kai M ^k   Ziemer, Mirjana ^l   Zimmer, Lisa ^m   Gutzmer, Ralf ⁿ  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^l UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^m UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Autoimmunity; Immune related adverse events; Ipilimumab; Melanoma

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLITIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOPHYSITIS; MACULOPAPULAR RASH; MALE; METASTATIC MELANOMA; NEUROLOGIC DISEASE; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN DISEASE; ULCERATIVE COLITIS; VITILIGO; COMPLICATION; FOLLOW UP; MELANOMA; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85042611949     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-018-2134-z     Document Type: Article

References (21)

1. Ma Q, Shilkrut M, Li M, Barber BL, Zhao Z (2018) Prevalence of autoimmune comorbidities in patients with metastatic melanoma in the US. Value Health 19(3):A135
2. Johnson DB, Sullivan RJ, Ott PA, Carlino MS4, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder E, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234–240
3. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368–376
4. Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24–32
5. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8:e53745
6. Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, Zimmer L, Sendl A, Gutzmer R (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7–18
7. Kyi C, Carvajal RD, Wolchok JD, Postow MA (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2:35
8. Bostwick AD, Salama AK, Hanks BA (2015) Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 3:19
9. Pedersen M, Andersen R, Nørgaard P, Jacobsen S, Thielsen P, Thor Straten P, Svane IM (2014) Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother 63:1341–1346
10. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J of Clin Oncology 27:6199–6206
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
12. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
13. Bender C, Dimitrakopoulou-Strauss A, Enk A, Hassel JC (2016) Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Ann Oncol 27:1353–1354
14. Blackmon JT, Viator TM, Conry RM (2016) Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromed 4:39–45
15. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225
16. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807–3814
17. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053
18. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688
19. Pavlov D, Marshall MA (2010) Association of adverse events and tumor response in melanoma patients treated with tremelimumab. J Clin Oncol. 10.1200/jco.2010.28.15_suppl.e13104
20. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM (2015) Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773–781
21. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206–1212